KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Operating Expenses (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Operating Expenses for 16 consecutive years, with $544.7 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses rose 344.59% to $544.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $927.6 million through Dec 2025, up 99.98% year-over-year, with the annual reading at $927.6 million for FY2025, 99.98% up from the prior year.
  • Operating Expenses for Q4 2025 was $544.7 million at Halozyme Therapeutics, up from $136.3 million in the prior quarter.
  • The five-year high for Operating Expenses was $544.7 million in Q4 2025, with the low at $38.3 million in Q1 2021.
  • Average Operating Expenses over 5 years is $122.2 million, with a median of $120.4 million recorded in 2022.
  • The sharpest move saw Operating Expenses dropped 9.85% in 2024, then soared 344.59% in 2025.
  • Over 5 years, Operating Expenses stood at $45.5 million in 2021, then surged by 135.3% to $107.0 million in 2022, then rose by 20.58% to $129.0 million in 2023, then fell by 5.04% to $122.5 million in 2024, then soared by 344.59% to $544.7 million in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $544.7 million, $136.3 million, and $123.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.